Physician profile
Christopher L Tebbit
NPI 1336316819
$2,199.78
in general payments reported to CMS, 2019-2025
12 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $14.11 · 2021: $133 · 2022: $529 · 2023: $24.89 · 2024: $437 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,097.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $355.65 | 2021-2025 | |
| Optinose US, INC. | $277.18 | 2019-2024 | |
| Acclarent, INC | $277.16 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $245.93 | 2022-2024 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $244.65 | 2019-2025 | Tezspire |
| Stryker Corporation | $182.26 | 2019 | |
| Integra Lifesciences Corporation | $164.78 | 2024 | Relieva Spinplus Nav, Trudi Probe, Inspira Air |
| Medtronic, INC. | $153.34 | 2025 | Stealthstation S8 Platform |
| Aerin Medical INC. | $134.22 | 2024 | |
| Glaxosmithkline, LLC. | $124.32 | 2025 | Nucala |
| Alcon Vision LLC | $24.89 | 2023 | Lensx |
| Acelrx Pharmaceuticals, INC. | $15.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Tebbit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.